In a report released today, Joseph Stringer from Needham maintained a Buy rating on Annexon Biosciences, with a price target of $11.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Stringer has given his Buy rating due to a combination of factors related to Annexon Biosciences’ recent developments and financial health. The company is currently engaged in ongoing regulatory discussions with the FDA concerning the BLA submission for tanruprubart in treating Guillain-Barré Syndrome, indicating potential progress in their pipeline. Additionally, Annexon is anticipating proof-of-concept data for their oral complement inhibitor program, ANX1502, by the end of 2025, which could further enhance their portfolio.
Moreover, the tanruprubart Phase 3 program for Geographic Atrophy is fully enrolled, with data expected in the second half of 2026, suggesting a well-advanced stage in clinical trials. Financially, Annexon reported a cash balance of $227 million as of the second quarter of 2025, which is projected to support operations into the second half of 2026, providing a stable financial runway. These elements combined suggest a promising outlook for the company, justifying the Buy rating.